Cardiac amyloidosis

References

• Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;114(3):529-38
   Web of Science ®Google Scholar
• Pomerance A. Senile cardiac amyloidosis. Br Heart J 1965;27(5):711-18
   Google Scholar
• Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79(7):1817-22
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Forsti A, et al. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health 2012;12:974
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349(6):583-96
   PubMed Web of Science ®Google Scholar
• Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2012 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2012;19(-4):167-270
   Google Scholar
• Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart 2011;97(1):75-84
   PubMed Web of Science ®Google Scholar
• Cotran RS, Kumar V, Collins T. Diseases of immunity. In: Robbins pathologic basis of disease. W.B. Saunders Company; Philadelphia, USA: 1999. p. 189-259
   Google Scholar
• WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ 1993;71(1):105-12
   Google Scholar
• Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997;337(13):898-909
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996;77(4):313-15
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32(1):45-59
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91(2):141-57
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, et al. The trnsthyretin Amyloidosis: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory agency approved drug. J Mol Biol 2012;421(2-3):185-203
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336(7):466-73
   PubMed Web of Science ®Google Scholar
• Falk RH. The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis 2002;12(1):141-3
   Google Scholar
• Lachman HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL(Primary) amyloidosis. N Engl J Med 2002;346(23):1786-91
   Google Scholar
• Dubrey SW, Falk RH. Amyloid heart disease. Br J Hosp Med (Lond) 2010;71(2):76-82
   Google Scholar
• Cornwell GG III, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983;75(4):618-23
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87(7):2843-5
   PubMed Web of Science ®Google Scholar
• Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165(12):1425-9
   PubMedGoogle Scholar
• Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006;15(5):287-90
   PubMed Web of Science ®Google Scholar
• Leone O, Boriani G, Chiappini B, et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J 2004;25(14):1237-41
   Google Scholar
• Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106(16):2091-7
   PubMed Web of Science ®Google Scholar
• Kristen AV, Schnabel PA, Winter B, et al. High prevalence of amyloid in 150 surgically removed heart valves–a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions. Cardiovasc Pathol 2010;19(4):228-35
   Google Scholar
• Iqbal S, Reehana S, Lawrence D. Unique type of isolated cardiac valvular amyloidosis. J Cardiothorac Surg 2006;1:38
   Google Scholar
• Chamarthi B, Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997;80(9):1242-5
   PubMed Web of Science ®Google Scholar
• Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999;131(11):838-41
   Web of Science ®Google Scholar
• Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol 2000;85(7):849-53
   PubMed Web of Science ®Google Scholar
• Neben-Wittich MA, Wittich CM, Mueller PS, et al. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med 2005;118(11):1287
   Google Scholar
• Tyberg TI, Goodyer AV, Hurst VW III, et al. Left ventricular filling in differentiating restrictive amyloid cardiomyopathy and constrictive pericarditis. Am J Cardiol 1981;47(4):791-6
   Google Scholar
• Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 1983;143(8):1549-52
   PubMedGoogle Scholar
• Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005;96(7):982-4
   Google Scholar
• Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107(19):2440-5
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33(9):1120-7
   PubMed Web of Science ®Google Scholar
• Suhr OB, Anan I, Backman C, et al. Do troponin and B-natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? J Intern Med 2008;263(3):294-301
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361(9371):1787-9
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22(18):3751-7
   PubMed Web of Science ®Google Scholar
• Cheng ZW, Tian Z, Kang L, et al. Electrocardiographic and echocardiographic features of patients with primary cardiac amyloidosis. Zhonghua Xin Xue Guan Bing Za Zhi 2010;38(7):606-9
   Google Scholar
• Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95(4):535-7
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120(13):1203-12
   PubMed Web of Science ®Google Scholar
• Falk RH, Rubinow A, Cohen AS. Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 1984;3(1):107-13
   PubMed Web of Science ®Google Scholar
• Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 2004;43(3):410-15
   PubMed Web of Science ®Google Scholar
• Kristen AV, Perz JB, Schonland SO, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007;26(12):1313-19
   PubMed Web of Science ®Google Scholar
• Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3(4):333-42
   PubMed Web of Science ®Google Scholar
• Migrino RQ, Mareedu RK, Eastwood D, et al. Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis. J Am Soc Echocardiogr 2009;22(12):1396-402
   Google Scholar
• Selvanayagam JB, Hawkins PN, Paul B, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50(22):2101-10
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005;79(4):319-28
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18(12):1440-1463
   PubMed Web of Science ®Google Scholar
• Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119(18):2490-7
   PubMed Web of Science ®Google Scholar
• Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol 1997;80(4):486-92
   PubMed Web of Science ®Google Scholar
• Siqueira-Filho AG, Cunha CL, Tajik AJ, et al. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981;63(1):188-96
   Google Scholar
• Park SJ, Miyazaki C, Bruce CJ, et al. Left ventricular torsion by two-dimensional speckle tracking echocardiography in patients with diastolic dysfunction and normal ejection fraction. J Am Soc Echocardiogr 2008;21(10):1129-37
   PubMed Web of Science ®Google Scholar
• Porciani MC, Cappelli F, Perfetto F, et al. Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography 2010;27(9):1061-8
   PubMed Web of Science ®Google Scholar
• Kusunose K, Yamada H, Iwase T, et al. Images in cardiovascular medicine. Cardiac magnetic resonance imaging and 2-dimensional speckle tracking echocardiography in secondary cardiac amyloidosis. Circ J 2010;74(7):1494-6
   Google Scholar
• Sun JP, Stewart WJ, Yang XS, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103(3):411-15
   PubMed Web of Science ®Google Scholar
• Maciver DH, Townsend M. A novel mechanism of heart failure with normal ejection fraction. Heart 2008;94(4):446-9
   Google Scholar
• Koyama J, Ray-Sequin PA, Davidoff R, Falk RH. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 2002;89(9):1067-71
   Google Scholar
• Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol 2008;101(7):1039-45
   PubMed Web of Science ®Google Scholar
• Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 2003;107(19):2446-52
   PubMed Web of Science ®Google Scholar
• Swanton RH, Brooksby IA, Davies MJ, et al. Systolic and diastolic ventricular function in cardiac amyloidosis. Studies in six cases diagnosed with endomyocardial biopsy. Am J Cardiol 1977;39(5):658-64
   Google Scholar
• Nishimura RA, Carabello BA. Hemodynamics in the cardiac catherization laboratory in the 21st century. Circulation 2012;125(17):2138-50
   PubMed Web of Science ®Google Scholar
• Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100(19):1992-2002
   PubMed Web of Science ®Google Scholar
• Shah DJ, Judd RM, Kim RJ. Technology insight: MRI of the myocardium. Nat Clin Pract Cardiovasc Med 2005;2(11):597-605; quiz 606
   PubMedGoogle Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111(2):186-93
   PubMed Web of Science ®Google Scholar
• Maceira AM, Prasad SK, Hawkins PN, et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54
   PubMed Web of Science ®Google Scholar
• Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3(2):155-64
   PubMed Web of Science ®Google Scholar
• Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 2005;26(15):1461-74
   PubMed Web of Science ®Google Scholar
• Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51(10):1022-30
   PubMed Web of Science ®Google Scholar
• Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, et al. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging 2012;5(9):897-907
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6(4):488-97
   PubMed Web of Science ®Google Scholar
• Chen W, Dilsizian V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr Cardiol Rep 2012;14(2):226-33
   Google Scholar
• Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med 2013;54(2):213-20
   PubMed Web of Science ®Google Scholar
• de Haro-del Moral FJ, Sanchez-Lajusticia A, Gomez-Bueno M, et al. Role of cardiac scintigraphy with (9)(9)mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev Esp Cardiol (Engl Ed) 2012;65(5):440-6
   Google Scholar
• Kieninger B, Eriksson M, Kandolf R, et al. Amyloid in endomyocardial biopsies. Virchows Arch 2010;456(5):523-32
   Google Scholar
• Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian Blue stain for amyloid in cardiac pathology. J Clin Pathol 1976;29(1):22-6
   Google Scholar
• Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004;147(5):919-23
   PubMed Web of Science ®Google Scholar
• Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol 2004;30(3):178-81
   Google Scholar
• Mueller PS, Edwards WD, Gertz MA. Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 2000;109(3):181-8
   PubMed Web of Science ®Google Scholar
• Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995;75(4):246-50
   Google Scholar
• Yamano S, Motomiya K, Akai Y, et al. Primary systemic amyloidosis presenting as angina pectoris due to intramyocardial coronary artery involvement: a case report. Heart Vessels 2002;16(4):157-60
   Google Scholar
• Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993;104(2):618-20
   PubMed Web of Science ®Google Scholar
• Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63(6):1285-8
   PubMed Web of Science ®Google Scholar
• Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices–summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/NASPE committee to update the 1998 pacemaker guidelines). J Am Coll Cardiol 2002;40(9):1703-19
   PubMed Web of Science ®Google Scholar
• Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5(2):235-40
   PubMed Web of Science ®Google Scholar
• Sack FU, Kristen A, Goldschmidt H, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg 2008;33(2):257-62
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Burke MM, Khaghani A, et al. Long term results of heart transplantation in patients with amyloid heart disease. Heart 2001;85(2):202-7
   Google Scholar
• Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103(8):2936-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110(2):787-8
   PubMed Web of Science ®Google Scholar
• Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116(4):522-8
   PubMed Web of Science ®Google Scholar
• Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105(7):2949-51
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109(2):457-64
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109(2):465-70
   PubMed Web of Science ®Google Scholar
• Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012;119(21):4860-7
   PubMed Web of Science ®Google Scholar
• Specter R, Sanchorawala V, Seldin DC, et al. Kidney dysfunction during lenalidomide treatment for AL amyloidosis. Nephrol Dial Transplant 2011;26(3):881-6
   PubMed Web of Science ®Google Scholar
• Tapan U, Seldin DC, Finn KT, et al. Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood 2010;116(23):5071-2
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119(19):4391-4
   PubMed Web of Science ®Google Scholar
• Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012;119(19):4387-90
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140(2):85-93
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118(16):4346-52
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after. 2006;Bone Marrow Transplant 2011;46(7):970-5
   Google Scholar
• Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110(10):3561-3
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104(6):1881-7
   PubMed Web of Science ®Google Scholar
• Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119(5):1117-22
   PubMed Web of Science ®Google Scholar
• Ruberg FL, BErk JL. Transthyretin (TTR) Cardiac Amyloidosis. Circulation 2012;126(10):1286-300
   PubMed Web of Science ®Google Scholar
• Ando Y, Coelho T, BErk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orpahanet J Rare Dis 2013;8(31):1-18
   Google Scholar
• Herlinius G, Wilczek HE, Larsson M, et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry. Transplantation. 2004;77(1):64-71
   Google Scholar
• Dubrey SW, Burke MM, Hawkins PN, Banner NB. Cardiac transplant for amyloid heart disease: the United Kingdom Experience. J Heart Lung Transplant 2004;23(10):1142-53
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. New Engl J Med 2013;369(9):819-29
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336(17):1202-7
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Connors LH, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104(14):1594-7
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94(8):1008-10
   PubMed Web of Science ®Google Scholar